US Inhaled Insulin Dose Titration Study
Public ClinicalTrials.gov record NCT00246623. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Open-Label, Multicenter Study Assessing the Effects of Forced Exubera Dose Titration on Glycemic Control in Patients With Suboptimally Controlled Type 2 Diabetes on Two or More Oral Antidiabetic Agents
Study identification
- NCT ID
- NCT00246623
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Pfizer
- Industry
- Enrollment
- 120 participants
Conditions and interventions
Conditions
Interventions
- 24-hour continuous glucose monitoring (at select sites) Procedure
- 8-point glucose diary (to assess pre- and post prandial glucoses) Procedure
- Exubera (inhaled insulin) Drug
- Hypoglycemic Event Monitoring Procedure
- Laboratory Assessments Procedure
- Meal Tolerance Test Procedure
- Nutritional Counseling and Diabetes Education Behavioral
- Pulmonary Function Testing Procedure
Procedure · Drug · Behavioral
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2005
- Primary completion
- Not listed
- Completion
- Feb 28, 2007
- Last update posted
- Feb 7, 2008
2005 – 2007
United States locations
- U.S. sites
- 16
- U.S. states
- 11
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Birmingham | Alabama | — | — |
| Pfizer Investigational Site | Los Angeles | California | — | — |
| Pfizer Investigational Site | New Britain | Connecticut | — | — |
| Pfizer Investigational Site | Norwalk | Connecticut | — | — |
| Pfizer Investigational Site | Hollywood | Florida | — | — |
| Pfizer Investigational Site | Atlanta | Georgia | — | — |
| Pfizer Investigational Site | Boise | Idaho | — | — |
| Pfizer Investigational Site | Hayden | Idaho | — | — |
| Pfizer Investigational Site | Baton Rouge | Louisiana | — | — |
| Pfizer Investigational Site | Boston | Massachusetts | — | — |
| Pfizer Investigational Site | Albany | New York | — | — |
| Pfizer Investigational Site | Syracuse | New York | — | — |
| Pfizer Investigational Site | Dallas | Texas | — | — |
| Pfizer Investigational Site | El Paso | Texas | — | — |
| Pfizer Investigational Site | San Antonio | Texas | — | — |
| Pfizer Investigational Site | Bennington | Vermont | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00246623, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 7, 2008 · Synced Apr 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00246623 live on ClinicalTrials.gov.